Company Overview
| Stock Name | Medlive |
|---|---|
| Stock Code | 02192 |
| Company Full Name | To be extracted |
| Industry | Healthcare |
| Principal Activities | 我們是中國最大的在線專業醫師平台,自主開發的醫脈通平台為中國製藥及醫療設備公司提供精準數字醫療營銷服務,並為醫師提供專業醫學信息及臨床決策支持,亦為患者提供智能患者管理解決方案及為醫院提供臨床研究數據管理工具。 |
| Listing Date | 2021-07-15 |
| Listing Rules Era | Old Rules |
| Listing Rules Chapter | To be extracted |
| Weighted Voting Rights (WVR) | No |
| Registered Address (Mainland China) | 中國北京朝陽區朝陽北路白家樓甲1號紅莊國際文化保稅創新園 |
| Business Address (Hong Kong) | 香港勿地臣街1號時代廣場二座31樓 |
| Place of Incorporation | To be extracted |
| Listing Method | To be extracted |
| Listing Board | Main Board |
| Website | www.medlive.cn |
| Share Registrar | 卓佳证券登记有限公司 (Tricor Investor Services Limited) |
| Registrar Contact | (852)2980 1333 |
| A-Share/US Dual Listing | No |
Offering Information
| Offering Mechanism | To be extracted |
|---|---|
| Offer Price | HK$ 27.20 / shares |
| Offer Price Range | Final offer price only, no range |
| Lot Size | 500 shares |
| Entry Threshold | HK$ 13,600 |
| Par Value | RMB 1e-05 / shares |
| Offer Period | 2021-06-30 to 2021-07-07 |
| Global Offering Shares | 155,096,000 shares |
| HK Public Offer Shares (Initial) | 15,510,000 shares (10.0%) |
| Public Offer Lots (Initial) | 31,020lots (Pool A15,510lots,Pool B15,510lots) |
| International Placing Shares (Initial) | 139,586,000 shares (90.0%) |
| Offer Ratio | ~10.0% |
| Total Shares Post-IPO | 690,176,000 shares |
| Greenshoe (Over-allotment Option) | Yes |
| Stabilizing Manager (Greenshoe) | To be extracted |
| Cornerstone Share | 40.5% |
| Clawback Tiers | To be extracted |
| Reallocation Option | No |
| Total Global Offering Size | HK$ 4,218,611,200 |
Subscription Tiers
Minimum subscription unit: 1 lot. Subscription amount ≤ HK$5,000,000 is Pool A, > HK$5,000,000 is Pool B.
Pool A
| Lots Subscribed | Shares Subscribed | Subscription Amount (HKD) |
|---|---|---|
| 1 lots | 500 | HK$ 13,600 |
| 2 lots | 1,000 | HK$ 27,200 |
| 3 lots | 1,500 | HK$ 40,800 |
| 4 lots | 2,000 | HK$ 54,400 |
| 5 lots | 2,500 | HK$ 68,000 |
| 6 lots | 3,000 | HK$ 81,600 |
| 7 lots | 3,500 | HK$ 95,200 |
| 8 lots | 4,000 | HK$ 108,800 |
| 9 lots | 4,500 | HK$ 122,400 |
| 10 lots | 5,000 | HK$ 136,000 |
| 12 lots | 6,000 | HK$ 163,200 |
| 14 lots | 7,000 | HK$ 190,400 |
| 16 lots | 8,000 | HK$ 217,600 |
| 18 lots | 9,000 | HK$ 244,800 |
| 20 lots | 10,000 | HK$ 272,000 |
| 30 lots | 15,000 | HK$ 408,000 |
| 40 lots | 20,000 | HK$ 544,000 |
| 50 lots | 25,000 | HK$ 680,000 |
| 60 lots | 30,000 | HK$ 816,000 |
| 70 lots | 35,000 | HK$ 952,000 |
| 80 lots | 40,000 | HK$ 1,088,000 |
| 90 lots | 45,000 | HK$ 1,224,000 |
| 100 lots | 50,000 | HK$ 1,360,000 |
| 120 lots | 60,000 | HK$ 1,632,000 |
| 140 lots | 70,000 | HK$ 1,904,000 |
| 160 lots | 80,000 | HK$ 2,176,000 |
| 180 lots | 90,000 | HK$ 2,448,000 |
| 200 lots | 100,000 | HK$ 2,720,000 |
Pool B
| Lots Subscribed | Shares Subscribed | Subscription Amount (HKD) |
|---|---|---|
| 400 lots | 200,000 | HK$ 5,440,000 |
| 600 lots | 300,000 | HK$ 8,160,000 |
| 800 lots | 400,000 | HK$ 10,880,000 |
| 1,000 lots | 500,000 | HK$ 13,600,000 |
| 1,200 lots | 600,000 | HK$ 16,320,000 |
| 1,400 lots | 700,000 | HK$ 19,040,000 |
| 1,600 lots | 800,000 | HK$ 21,760,000 |
| 1,800 lots | 900,000 | HK$ 24,480,000 |
| 2,000 lots | 1,000,000 | HK$ 27,200,000 |
| 4,000 lots | 2,000,000 | HK$ 54,400,000 |
| 6,000 lots | 3,000,000 | HK$ 81,600,000 |
| 8,000 lots | 4,000,000 | HK$ 108,800,000 |
| 10,000 lots | 5,000,000 | HK$ 136,000,000 |
| 12,000 lots | 6,000,000 | HK$ 163,200,000 |
| 14,000 lots | 7,000,000 | HK$ 190,400,000 |
| 15,510 lots | 7,755,000 | HK$ 210,936,000 |
Stock Connect Inclusion Analysis
| HK Market Cap | HK$ 5.81B |
|---|---|
| Analysis Result | Already included in Stock Connect (both) |
Valuation & Financials
| Market Cap (at Offer Price) | HK$ 18,772,787,200 |
|---|---|
| Pre-IPO Valuation (Last Round) | Not disclosed |
| P/E Ratio | Not disclosed |
| Profit/Loss Status | 盈利約人民幣85.2百萬元 |
| Period-End Cash Balance | To be extracted |
| Listing Expenses | To be extracted |
| Listing Expenses / Funds Raised | To be extracted |
| Total Pre-IPO Investment | To be extracted |
Financial Data
Unit:
'000
RMB
Income Statement
| Item | 2018 | 2019 | 2020 |
|---|---|---|---|
| Revenue | 83,463 | 121,569 | 213,529 |
| Cost of sales | -33,573 | -44,379 | -57,293 |
| Gross profit | 49,890 | 77,190 | 156,236 |
| Other income and gains, net | 99 | 96 | 1,543 |
| Selling and distribution expenses | -7,080 | -8,588 | -20,037 |
| Administrative expenses | -26,375 | -31,391 | -32,640 |
| Operating profit | 16,459 | 37,294 | 105,057 |
| Net finance costs | -439 | -296 | -209 |
| Profit before tax | 16,020 | 36,998 | 104,848 |
| Income tax expense | -1,831 | -5,728 | -19,651 |
| Profit for the year | 14,189 | 31,270 | 85,197 |
| Profit attributable to owners | 14,189 | 31,270 | 85,197 |
Balance Sheet
| Item | 2018 | 2019 | 2020 |
|---|---|---|---|
| Cash and cash equivalents | 16,530 | 38,883 | 147,095 |
| Trade and bills receivables | 26,024 | 35,643 | 42,480 |
| Total current assets | 56,486 | 101,033 | 208,362 |
| Total current liabilities | 30,339 | 44,991 | 64,078 |
| Total equity | 34,958 | 66,232 | 151,414 |
| Equity attributable to owners | 34,958 | 66,232 | 151,414 |
Cash Flow Statement
| Item | 2018 | 2019 | 2020 |
|---|---|---|---|
| Net cash from operating activities | 22,091 | 28,203 | 111,048 |
| Net cash from investing activities | -3,101 | -2,426 | 13 |
| Net cash from financing activities | -5,846 | -3,428 | -2,834 |
| Net increase in cash | 13,144 | 22,349 | 108,227 |
| Depreciation of PP&E | 1,307 | 1,944 | 2,658 |
| Depreciation of right-of-use assets | 3,048 | 2,888 | 2,658 |
| Purchase of PP&E | -3,101 | -2,426 | -626 |
Income Statement
Balance Sheet
Cash Flow Statement
Source: Accountants' Report and Audited Consolidated Financial Statements
| First Day Close | HK$ 31.0 |
|---|---|
| First Day Open | HK$ 28.9 |
| First Day Change | 13.97% |
| First Day Volume | 115437000.0 |
| First Day Turnover | 3544610000.0 |
| Use of Proceeds | 1、約40%(約1,600.4百萬港元)擬用于在未來三至五年內擴展業務;
2、約30%(約1,200.3百萬港元)擬用于在未來三至五年內投資技術及提高研發能力;
3、約20%(約800.2百萬港元)擬用于有精心挑選戰略投資或收購機會;
4、約10%(約400.1百萬港元)擬用作一般補充營運資金及其他一般企業用途。 |
Underwriting Syndicate
Overall Coordinators (3)
Joint Bookrunners (3)
Joint Lead Managers (3)
Cornerstone Investors
| # | Investor Name | Investment Amount | Shares Subscribed | % of Offer Shares | % of Total Shares | Lock-up Period | Est. Unlock Date |
|---|---|---|---|---|---|---|---|
| 1 | Fidelity International | 310,501,600 HKD | — | 7.36% | — | 6 months | 2022-01-15 |
| 2 | Fidelity Management & Research (Hong Kong) Limited | 310,501,600 HKD | — | 7.36% | — | 6 months | 2022-01-15 |
| 3 | GIC Private Limited | 310,501,600 HKD | — | 7.36% | — | 6 months | 2022-01-15 |
| 4 | Matthews Asia Funds | 155,244,000 HKD | — | 3.68% | — | 6 months | 2022-01-15 |
| 5 | OrbiMed Funds | 155,244,000 HKD | — | 3.68% | — | 6 months | 2022-01-15 |
| 6 | Springhill Master Fund Limited | 155,244,000 HKD | — | 3.68% | — | 6 months | 2022-01-15 |
| 7 | Tencent Mobility Limited | 310,501,600 HKD | — | 7.36% | — | 6 months | 2022-01-15 |
Directors & Management
| Position | Chinese name | English Name |
|---|---|---|
| Chairman | 田立平 | — |
| Company Secretary | 楊艷玲、司徒嘉怡 | — |
No director data available.
Major Shareholders
| Major Shareholders & Holdings | Tiantian及M3各自持有緊隨全球發售完成後已發行股本約38.8%;Tiantian由田立平、田立新及田立軍分別持有48%、37%及15%股權,M3由Sony Group Corporation持有約33.95%股權。 |
|---|




